NCT04617522: A Phase 1, Dose Escalation Study in Subjects With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with symptomatic, untreated, or actively progressing CNS metastases and/or leptomeningeal disease – see trial for details

Comments are closed.

Up ↑